Inogen (INGN) Aktsia Kursus
Inogen Kursus
Over the last 14 years Inogen grew revenue by 19,0% annually, reaching 348,67 M USD. Earnings per share have grown at 58,1% per year over the last 7 years. For Inogen, the net margin of â6,5% is down versus â1,8% a few years ago. The consensus 12-month price target for Inogen is 13,26 USD, about 130,6% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy â an overall Buy consensus. The stock trades about 3% above its 52-week low.
Inogen aktsiahinnad
Detailid
Kurs
âĂlevaade
Aktsiahinna diagramm pakub detailseid ja dĂŒnaamilisi ĂŒlevaateid Inogen-aktsia sooritusest, kuvades igapĂ€evaselt, nĂ€dalaselt vĂ”i kuuselt kokkuvĂ”etud kursid. Kasutajad saavad erinevate ajarahmade vahel liikudes aktsia ajalugu pĂ”hjalikult analĂŒĂŒsida ja teha teadlikke investeerimisotsuseid.
Intraday-funktsioon
Intraday-funktsioon pakub reaalajas andmeid ja vÔimaldab investoritel jÀlgida Inogen-aktsia kursikÔikumisi kauplemispÀeva jooksul, et teha Ôigeaegseid ja strateegilisi investeerimisotsuseid.
Kogutulu ja suhteline hinnamuutus
Vaadake Inogen-aktsia kogutulu, et hinnata selle kasumlikkust ajas. Suhtelise hinnamuutuse, mis pĂ”hineb valitud ajarahma esimesel saadaoleval kursil, annab ĂŒlevaate aktsia toimivusest ja aitab hinnata selle investeerimispotentsiaali.
Interpretatsioon ja investeering
Kasutage aktsiahinna diagrammis esitatud pĂ”hjalikke andmeid, et analĂŒĂŒsida Inogen turutrende, hinnaliikumisi ja potentsiaalseid tulusid. Tehke teadlikke investeerimisotsuseid, vĂ”rreldes erinevaid ajarahmasid ja hinnates Intraday andmeid optimeeritud portfelli haldamiseks.
| KuupÀev | Inogen Hind |
|---|---|
| 14.8.2026 | 5,75 USD |
| 13.8.2026 | 5,81 USD |
| 12.8.2026 | 5,88 USD |
| 10.8.2026 | 6,02 USD |
| 7.8.2026 | 6,05 USD |
| 6.8.2026 | 6,49 USD |
| 5.8.2026 | 6,53 USD |
| 4.8.2026 | 6,83 USD |
| 3.8.2026 | 6,71 USD |
| 31.7.2026 | 6,45 USD |
| 30.7.2026 | 6,42 USD |
| 29.7.2026 | 6,44 USD |
| 27.7.2026 | 6,38 USD |
| 23.7.2026 | 6,32 USD |
| 22.7.2026 | 6,51 USD |
| 21.7.2026 | 6,43 USD |
| 20.7.2026 | 6,40 USD |
| 17.7.2026 | 6,57 USD |
| 16.7.2026 | 6,66 USD |
| 15.7.2026 | 6,41 USD |
| 14.7.2026 | 6,33 USD |
| 13.7.2026 | 6,75 USD |
| 10.7.2026 | 6,54 USD |
| 9.7.2026 | 6,53 USD |
| 8.7.2026 | 6,42 USD |
| 7.7.2026 | 6,54 USD |
| 6.7.2026 | 6,64 USD |
| 2.7.2026 | 6,60 USD |
| 1.7.2026 | 6,65 USD |
| 30.6.2026 | 6,45 USD |
| 29.6.2026 | 6,93 USD |
| 26.6.2026 | 6,94 USD |
| 25.6.2026 | 6,78 USD |
| 24.6.2026 | 6,76 USD |
| 23.6.2026 | 6,54 USD |
| 22.6.2026 | 6,36 USD |
| 18.6.2026 | 6,41 USD |
| 17.6.2026 | 6,37 USD |
| 16.6.2026 | 6,41 USD |
| 15.6.2026 | 6,46 USD |
| 12.6.2026 | 6,40 USD |
| 11.6.2026 | 6,30 USD |
| 10.6.2026 | 6,53 USD |
| 9.6.2026 | 6,35 USD |
| 8.6.2026 | 6,06 USD |
| 5.6.2026 | 6,41 USD |
| 4.6.2026 | 6,31 USD |
| 3.6.2026 | 5,98 USD |
| 2.6.2026 | 6,09 USD |
| 1.6.2026 | 6,09 USD |
| 29.5.2026 | 6,49 USD |
| 28.5.2026 | 6,54 USD |
| 27.5.2026 | 6,58 USD |
| 26.5.2026 | 6,58 USD |
| 22.5.2026 | 6,40 USD |
| 21.5.2026 | 6,41 USD |
| 20.5.2026 | 6,34 USD |
| 19.5.2026 | 6,45 USD |
| 18.5.2026 | 6,30 USD |
| 15.5.2026 | 6,38 USD |
| 14.5.2026 | 6,80 USD |
| 13.5.2026 | 6,81 USD |
| 12.5.2026 | 6,68 USD |
| 11.5.2026 | 6,62 USD |
| 8.5.2026 | 7,02 USD |
| 7.5.2026 | 7,19 USD |
| 6.5.2026 | 7,11 USD |
| 5.5.2026 | 7,05 USD |
| 4.5.2026 | 6,97 USD |
| 22.4.2026 | 7,15 USD |
| 21.4.2026 | 6,96 USD |
| 20.4.2026 | 6,95 USD |
| 17.4.2026 | 6,82 USD |
| 16.4.2026 | 6,59 USD |
| 15.4.2026 | 6,20 USD |
| 14.4.2026 | 6,34 USD |
| 13.4.2026 | 6,45 USD |
| 10.4.2026 | 6,33 USD |
| 9.4.2026 | 6,66 USD |
| 8.4.2026 | 6,67 USD |
| 7.4.2026 | 6,80 USD |
| 6.4.2026 | 6,36 USD |
| 2.4.2026 | 6,21 USD |
| 1.4.2026 | 6,27 USD |
| 31.3.2026 | 6,18 USD |
| 30.3.2026 | 6,11 USD |
| 27.3.2026 | 6,19 USD |
| 26.3.2026 | 6,51 USD |
| 25.3.2026 | 6,42 USD |
| 24.3.2026 | 6,32 USD |
| 23.3.2026 | 6,45 USD |
| 20.3.2026 | 6,10 USD |
| 19.3.2026 | 6,16 USD |
| 18.3.2026 | 6,16 USD |
| 17.3.2026 | 6,20 USD |
| 16.3.2026 | 6,13 USD |
| 13.3.2026 | 6,06 USD |
| 12.3.2026 | 6,10 USD |
| 11.3.2026 | 6,23 USD |
| 10.3.2026 | 6,22 USD |
| 9.3.2026 | 6,36 USD |
| 6.3.2026 | 6,47 USD |
| 5.3.2026 | 6,55 USD |
| 4.3.2026 | 6,31 USD |
| 3.3.2026 | 6,21 USD |
| 2.3.2026 | 6,18 USD |
| 27.2.2026 | 6,10 USD |
| 26.2.2026 | 5,92 USD |
| 25.2.2026 | 6,01 USD |
| 24.2.2026 | 5,84 USD |
| 23.2.2026 | 5,77 USD |
| 20.2.2026 | 5,79 USD |
| 19.2.2026 | 5,83 USD |
| 18.2.2026 | 5,83 USD |
| 17.2.2026 | 5,69 USD |
| 16.2.2026 | 5,69 USD |
| 13.2.2026 | 5,76 USD |
| 12.2.2026 | 5,76 USD |
| 11.2.2026 | 5,79 USD |
| 10.2.2026 | 6,13 USD |
| 9.2.2026 | 5,75 USD |
| 8.2.2026 | 5,59 USD |
| 6.2.2026 | 5,66 USD |
| 5.2.2026 | 5,66 USD |
| 4.2.2026 | 5,66 USD |
| 3.2.2026 | 5,84 USD |
| 2.2.2026 | 5,95 USD |
| 1.2.2026 | 6,00 USD |
| 30.1.2026 | 5,90 USD |
| 29.1.2026 | 5,90 USD |
| 28.1.2026 | 5,82 USD |
| 27.1.2026 | 5,86 USD |
| 26.1.2026 | 5,89 USD |
| 25.1.2026 | 6,01 USD |
| 23.1.2026 | 6,03 USD |
| 22.1.2026 | 6,03 USD |
| 21.1.2026 | 6,22 USD |
| 20.1.2026 | 6,36 USD |
| 19.1.2026 | 6,21 USD |
| 16.1.2026 | 6,25 USD |
| 15.1.2026 | 6,25 USD |
| 14.1.2026 | 6,45 USD |
| 13.1.2026 | 6,50 USD |
| 12.1.2026 | 6,22 USD |
| 11.1.2026 | 6,21 USD |
| 9.1.2026 | 7,03 USD |
| 8.1.2026 | 7,03 USD |
| 7.1.2026 | 7,22 USD |
| 6.1.2026 | 7,32 USD |
| 5.1.2026 | 6,79 USD |
| 4.1.2026 | 6,65 USD |
| 2.1.2026 | 6,63 USD |
| 1.1.2026 | 6,63 USD |
| 31.12.2025 | 6,72 USD |
| 30.12.2025 | 6,72 USD |
| 29.12.2025 | 6,72 USD |
| 28.12.2025 | 6,71 USD |
| 26.12.2025 | 6,80 USD |
| 25.12.2025 | 6,80 USD |
| 24.12.2025 | 6,67 USD |
| 23.12.2025 | 6,67 USD |
| 22.12.2025 | 6,68 USD |
| 21.12.2025 | 6,75 USD |
| 19.12.2025 | 6,71 USD |
| 18.12.2025 | 6,71 USD |
| 17.12.2025 | 6,83 USD |
| 16.12.2025 | 6,82 USD |
| 15.12.2025 | 6,81 USD |
| 14.12.2025 | 6,83 USD |
| 12.12.2025 | 7,06 USD |
| 11.12.2025 | 7,06 USD |
| 10.12.2025 | 7,02 USD |
| 9.12.2025 | 6,91 USD |
| 8.12.2025 | 6,72 USD |
| 7.12.2025 | 6,67 USD |
| 5.12.2025 | 6,94 USD |
| 4.12.2025 | 6,94 USD |
| 3.12.2025 | 6,99 USD |
| 2.12.2025 | 6,91 USD |
| 1.12.2025 | 6,74 USD |
| 30.11.2025 | 6,95 USD |
| 28.11.2025 | 7,08 USD |
| 27.11.2025 | 7,08 USD |
| 26.11.2025 | 7,12 USD |
| 25.11.2025 | 7,12 USD |
| 24.11.2025 | 7,09 USD |
| 23.11.2025 | 7,08 USD |
| 21.11.2025 | 6,88 USD |
| 20.11.2025 | 6,88 USD |
| 19.11.2025 | 6,59 USD |
| 18.11.2025 | 6,69 USD |
| 17.11.2025 | 6,85 USD |
| 16.11.2025 | 6,71 USD |
| 14.11.2025 | 6,90 USD |
| 13.11.2025 | 6,90 USD |
| 12.11.2025 | 6,88 USD |
| 11.11.2025 | 7,09 USD |
| 10.11.2025 | 6,99 USD |
| 9.11.2025 | 7,02 USD |
| 7.11.2025 | 6,99 USD |
| 6.11.2025 | 6,99 USD |
| 5.11.2025 | 7,03 USD |
| 4.11.2025 | 7,39 USD |
| 3.11.2025 | 8,06 USD |
| 2.11.2025 | 8,21 USD |
| 31.10.2025 | 8,24 USD |
| 30.10.2025 | 8,24 USD |
| 29.10.2025 | 8,17 USD |
| 28.10.2025 | 8,41 USD |
| 27.10.2025 | 8,53 USD |
| 26.10.2025 | 8,66 USD |
| 23.10.2025 | 8,77 USD |
| 22.10.2025 | 8,95 USD |
| 21.10.2025 | 8,85 USD |
| 20.10.2025 | 8,49 USD |
| 19.10.2025 | 8,58 USD |
| 16.10.2025 | 8,37 USD |
| 15.10.2025 | 8,51 USD |
| 14.10.2025 | 8,52 USD |
| 13.10.2025 | 8,37 USD |
| 12.10.2025 | 8,04 USD |
| 9.10.2025 | 8,16 USD |
| 8.10.2025 | 8,50 USD |
| 7.10.2025 | 8,69 USD |
| 6.10.2025 | 8,59 USD |
| 5.10.2025 | 8,43 USD |
| 2.10.2025 | 8,65 USD |
| 1.10.2025 | 8,53 USD |
| 30.9.2025 | 8,42 USD |
| 29.9.2025 | 8,17 USD |
| 28.9.2025 | 8,11 USD |
| 25.9.2025 | 8,22 USD |
| 24.9.2025 | 8,46 USD |
| 23.9.2025 | 8,43 USD |
| 22.9.2025 | 8,34 USD |
| 21.9.2025 | 8,66 USD |
| 18.9.2025 | 8,66 USD |
| 17.9.2025 | 8,79 USD |
| 16.9.2025 | 8,32 USD |
| 15.9.2025 | 8,50 USD |
| 14.9.2025 | 8,56 USD |
| 11.9.2025 | 8,54 USD |
| 10.9.2025 | 8,56 USD |
| 9.9.2025 | 8,32 USD |
| 8.9.2025 | 8,53 USD |
| 7.9.2025 | 8,45 USD |
| 4.9.2025 | 8,11 USD |
| 3.9.2025 | 8,12 USD |
| 2.9.2025 | 7,88 USD |
| 1.9.2025 | 8,10 USD |
| 28.8.2025 | 7,99 USD |
| 27.8.2025 | 7,96 USD |
| 26.8.2025 | 7,93 USD |
| 25.8.2025 | 7,99 USD |
| 24.8.2025 | 7,71 USD |
| 21.8.2025 | 7,75 USD |
| 20.8.2025 | 7,53 USD |
| 19.8.2025 | 7,37 USD |
| 18.8.2025 | 7,49 USD |
| 17.8.2025 | 7,55 USD |
Inogen tulu, EBIT, netkasum
3 aastat
5 aastat
10 aastat
25 aastat
Max
Details
Inogen Kasumiaruanne, Bilanss, Rahavoogude aruanne
 |
|---|
| MĂĂGITULUM USD |
| KĂIBENĂUDLUS% |
| BRUTOMARGE% |
| BRUTOSISSETULEKM USD |
| EBITM USD |
| EBIT MARGINAAL% |
| PUHASTULUM USD |
| KASUMINĂUDLUS% |
| AKTSIADM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 159,00 | 202,00 | 249,00 | 358,00 | 361,00 | 308,00 | 358,00 | 377,00 | 315,00 | 335,00 | 348,00 | 369,00 | 396,00 | 416,00 | 454,00 | 476,00 |
| 41,96 | 27,04 | 23,27 | 43,78 | 0,84 | â14,68 | 16,23 | 5,31 | â16,45 | 6,35 | 3,88 | 6,03 | 7,32 | 5,05 | 9,13 | 4,85 |
| 47,80 | 48,02 | 48,59 | 49,72 | 47,37 | 44,81 | 49,16 | 40,58 | 40,00 | 45,97 | 47,41 | 47,41 | 47,41 | 47,41 | 47,41 | 47,41 |
| 76,00 | 97,00 | 121,00 | 178,00 | 171,00 | 138,00 | 176,00 | 153,00 | 126,00 | 154,00 | 165,00 | 174,96 | 187,76 | 197,24 | 215,26 | 225,69 |
| 15,00 | 22,00 | 27,00 | 37,00 | 19,00 | â12,00 | 9,00 | â85,00 | â109,00 | â42,00 | â30,00 | â35,00 | â38,00 | â40,00 | â43,00 | â45,00 |
| 9,43 | 10,89 | 10,84 | 10,34 | 5,26 | â3,90 | 2,51 | â22,55 | â34,60 | â12,54 | â8,62 | â9,49 | â9,60 | â9,62 | â9,47 | â9,45 |
| 11,00 | 20,00 | 21,00 | 51,00 | 20,00 | â5,00 | â6,00 | â83,00 | â102,00 | â35,00 | â22,00 | â20,00 | â12,00 | â8,00 | 1,00 | 4,00 |
| 83,33 | 81,82 | 5,00 | 142,86 | â60,78 | â125,00 | 20,00 | 1283,33 | 22,89 | â65,69 | â37,14 | â9,09 | â40,00 | â33,33 | â112,50 | 300,00 |
| 19,83 | 21,36 | 22,17 | 22,60 | 21,88 | 22,04 | 22,71 | 22,93 | 23,31 | 23,65 | 27,18 | 27,18 | 27,18 | 27,18 | 27,18 | 27,18 |
Ăksikasjad
Kasumiaruande pÔhinÀitajad
âTulu ja tulude kasv
Tulu on iga kasumiaruande lĂ€htepunkt â see mÔÔdab kogu mĂŒĂŒki, mille Inogen teenib oma pĂ”hitegevusest. Tulude kasv (vĂ€ljendatuna aasta-aasta protsentmuutusena) on ĂŒks olulisemaid Ă€ri hoogu nĂ€itajaid. JĂ€tkusuutliku kasvu ĂŒle 10% aastas peetakse tavaliselt tugevaks, samas kui kahanev tulu on tĂ”sine hoiatusmĂ€rk, mis nĂ”uab uurimist.
Brutomarginaal
Brutomarginaal = (Tulu â MĂŒĂŒdud kaupade kulu) Ă· Tulu. See nĂ€itab, kui suur protsent igast tuluallikast Inogen sĂ€ilitab pĂ€rast otseseid tootmiskulusid. KĂ”rged brutomarginaalid (ĂŒle 50%) on tĂŒĂŒpilised varade kergetele ettevĂ”tetele nagu tarkvara ja kaubamĂ€rgid, samas kui kapitaliintensiivsed tööstused nagu tootmine töötavad sageli alla 30%. VĂ”rrelge Inogen brutomarginaalide tööstushaarad ja jĂ€lgige neid aja jooksul, et tuvastada paremnevat vĂ”i halvenevat hinnakirja vĂ”imsust.
EBIT ja EBIT-marginaal
EBIT mÔÔdab Ă€rikasum â mis jÀÀb alles pĂ€rast kĂ”igi Ă€rikulude (sealhulgas uurimis- ja arenduskulud, mĂŒĂŒgikulud ja halduskulud) lahutamist brutokasum. EBIT-marginaal nĂ€itab seda tulude protsendina. Kuna see vĂ€listab intressid ja maksud, vĂ”imaldab EBIT Ă”iglast vĂ”rdlust erinevate vĂ”lastruktuuride ja maksujurisdiktsioonidega ettevĂ”tete vahel. Kasvav EBIT-marginaal nĂ€itab paranevat operatiivset tĂ”husust.
Puhaskasum ja kasum aktsia kohta (EPS)
Puhaskasum on ettevĂ”tte lĂ”plik kasum pĂ€rast kĂ”iki kulusid, intresse ja makse. Puhaskasumi jagamine vĂ€ljaantud aktsiate arvuga annab teile EPS â kĂ”ige mĂ”jukaim aktsia hindamise nĂ€itaja. JĂ€rjepidev EPS kasv on pikaajalise aktsiahinna kalliduse peamine juhtnöörid. Kontrollige alati, kas EPS kasv pĂ€rineb tegeliku kasumi parandamisest vĂ”i aktsiate tagasiostust, mis vĂ€hendab aktsiate arvu.
VĂ€ljastatud aktsiad
Koguarv aktsiate Inogen on vÀljastanud. Kahanev aktsiate arv (tagasiostude kaudu) suurendab EPS-i ja signaliseerib juhtimise enesekindlust. Kasvav aktsiate arv (aktsiate emissiooni kaudu) lahjendab olemasolevate aktsionÀride osa. JÀlgige alati seda numbrit koos EPS-ga, et saada tÀielik pilt aktsia kohta juhitud vÀÀrtusest.
AnalĂŒĂŒtikute hinnangud
Prognoositud arvud esindavad professionaalse analĂŒĂŒtikute konsensuselamisi. VĂ”rrelge neid prognoose Inogen ajalooliste kasvumÀÀrade vastu, et hinnata, kas ootused on realistlikud. EttevĂ”te, kes korrapĂ€raselt ĂŒletab konsensuselameid, kipub nĂ€gema oma aktsiahind ajas taunitud, samas kui korduvad jÀÀmid kahjustavad investorite usaldust.
Inogen aktsia marginaalid
3 aastat
5 aastat
10 aastat
25 aastat
Max
Details
Inogen aktsia tulu, EBIT, kasum aktsia kohta
3 aastat
5 aastat
10 aastat
25 aastat
Max
Details
Inogen Ă€rimudel ja aktsia analĂŒĂŒs
Inogen Employees
3 aastat
5 aastat
10 aastat
25 aastat
Max
Details
Inogen Segmendid
Inogen kÀive regiooni jÀrgi
3 aastat
5 aastat
Max
Details
Inogen hindamine Ôiglase vÀÀrtuse alusel
Ăksikasjad
Ăiglase vÀÀrtuse hinnang
âMis on Ă”iglane vÀÀrtus?
Ăiglane vÀÀrtus on hinnang selle kohta, millega aktsia on tegelikult "vÀÀrt" selle finantsalusel, sĂ”ltumata praegusest turuhinnast. Kui arvutatud Ă”iglane vÀÀrtus ĂŒletab praegust aktsia hinda, vĂ”ib aktsia olla alahinnatud â ja vastupidi. See diagramm nĂ€itab kolme erinevat Ă”iglase vÀÀrtuse lĂ€henemist, et saaksite neid omavahel kontrollida.
Tulul pÔhinev Ôiglane vÀÀrtus
Arvutatakse korrutades praeguse kasum aktsia kohta (EPS) valitud mitmeaastase perioodi keskmise ajaloolise P/E suhtega. Mitme aasta jooksul silumamine filtreerib vĂ€lja ajutised tĂ”usud vĂ”i langused. Kui see Ă”iglane vÀÀrtus ĂŒletab turuhinda, viitab see sellele, et aktsia on odav vĂ”rreldes selle kasumitegemise vĂ”imega.
NĂ€ide: Ăiglane vÀÀrtus (kasum) 2022 = EPS 2022 Ă Keskmine P/E 2019â2021
Tulul pÔhinev Ôiglane vÀÀrtus
Tuletatud tulupooluse korrutamisel keskmise ajaloolise hinna ja mĂŒĂŒgi suhtega. See meetod on eriti kasulik ettevĂ”tete puhul, millel on volatiilne vĂ”i ajutiselt langev kasum, kuna mĂŒĂŒk kipub olema stabiilsem kui kasumid. See vastab kĂŒsimusele: "Millise hinnaga on turg ajalooliselt hinnanud selle ettevĂ”tte mĂŒĂŒgi dollarit?"
NĂ€ide: Ăiglane vÀÀrtus (kasum) 2022 = MĂŒĂŒk aktsia kohta 2022 Ă Keskmine P/S 2019â2021
Dividendil pÔhinev Ôiglane vÀÀrtus
Arvutatakse jagades dividendi aktsia kohta keskmise ajaloolise dividendi tootlusega. See lĂ€henemisviis on kĂ”ige asjakohane kĂŒpsete, jĂ€rjepidevalt dividende maksvate ettevĂ”tete jaoks. Kui saadud Ă”iglane vÀÀrtus on praegusest hinnast kĂ”rgem, tĂ€hendab see, et aktsia pakub paremat tootlust kui selle ajaloo keskmine.
NĂ€ide: Ăiglane vÀÀrtus (dividend) 2022 = Dividend aktsia kohta 2022 Ă· Keskmine tootlus 2019â2021
Kuidas seda diagrammi kasutada
Kui kĂ”ik kolm Ă”iglase vÀÀrtuse joont koonduvad praeguse hinna kohal, tugevdab see veenvust, et aktsia on alahinnatud. Kui nad hajuvad, uurige, miks â see vĂ”ib nĂ€idata struktuurimuutust marginaalidel, vĂ€ljamakse poliitikale vĂ”i kasvumÀÀrale. Paremalt poolel olevad edasiulatusvad hinnangud laiendavad analĂŒĂŒsi, kasutades prognoositavaid pĂ”hifaktoreid, aidates teil hinnata, kas praegune hind juba kajastab tuleviku kasvuootusi.
Inogen hindamine ajalooline P/E-suhtarv, EBIT-multiple ja P/S-suhtarv
Inogen aktsia aastane tootlus
Ăksikasjad
Aastane tootlus
âMida see diagramm nĂ€itab
See diagramm jagab aastase kogu tootluse kaheks komponendiks: hinna tootluseks (kasumid vÔi kahjumid aktsia hinna liikumisest) ja dividendi tootluseks (tulu, mis saadud dividendi maksest). Koos esindavad need kogu tootlust, mida investor oleks iga kalendriaasta jooksul teeninud.
Hinna tootlus
Hinna tootlus mÔÔdab protsendi muutust aktsia hinnas 1. jaanuaari ja 31. detsembri vahel igal aastal. Positiivsed tulpd nĂ€itavad, et aktsia tĂ”usis; negatiivsed tulbad nĂ€itavad langust. See on komponent, mille peale enamik investoreid keskendub, kuid see rÀÀgivad ainult osale lugu â eriti dividende maksavate aktsiate puhul.
Dividendi tootlus
Dividendi tootlus esindab aasta jooksul makstud dividendist saadud tulu, vĂ€ljendatuna alusaktsiate hinnaprotsendina. Kuigi see vĂ”ib nĂ€ida vĂ€ike igal aastal (tavaliselt 1â4% tuntud ettevĂ”tete jaoks), kumuleeruvad dividendid mĂ€rkimisvÀÀrselt kĂŒmnendite jooksul ja on ajalooliselt osutanud ligikaudu 40% kogu aktsiaturuil tootlusele.
Mida otsida
Uurige, kui palju aastaid nĂ€itas positiivseid ja negatiivseid tootlusi, et hinnata jĂ€rjepidevust. Aktsia, millel on enamasti positiivsed aastad ja vĂ€ikesed langused, viitab madalamale riskile. Samuti vĂ”rrelge aastast tootlust kohalike indeksitega â pidevalt turu ĂŒletamine on tugeva investeeringu tunnusjoon. Pööra tĂ€helepanu halvaimaele aastale: allapoole riski mĂ”istmine on sama tĂ€htis kui ĂŒlespoolse potentsiaali Ă€raaita.
Inogen vÀljaolevad aktsiad
3 aastat
5 aastat
10 aastat
25 aastat
Max
Details
Aktuaalsed Inogen prognoosid ja kursieelistused August 2026
AnalĂŒĂŒtikute kurssizihtpunktid 2026Inogen Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 22.5.2025 | Upgrade | HoldBuy | 70 | |
| 8.5.2025 | Maintained | Hold | â | |
| 9.4.2025 | Maintained | Hold | 70 | |
| 27.2.2025 | Maintained | Hold | 70 | |
| 26.2.2025 | Maintained | Hold | 70 | |
| 30.1.2025 | Maintained | Hold | 70 | |
| 14.1.2025 | Maintained | Hold | 70 | |
| 8.5.2024 | Maintained | Hold | â | |
| 15.2.2024 | Upgrade | Market PerformOutperform | â | |
| 8.11.2023 | Maintained | Underweight | 80 |
Eulerpool Reliability Score (0â100): measures how often a firmâs bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Inogen Tulemuste teadaandmised
Inogen Kasumiprognoosid ja kasumiĂŒllatused
| KuupÀev | EPS hinnang | EPS tegelik | Tulu hinnang | Aktsia reaktsioon | Aruande kvartal |
|---|---|---|---|---|---|
| 6.8.2026 | â0,16USD | - | 97,14 MUSD | - | 2026 Q2 |
| 5.5.2026 | â0,29USD | - | 84,00 MUSD | - | 2026 Q1 |
| 24.2.2026 | â0,36USD | - | 86,75 MUSD | - | 2025 Q4 |
| 7.8.2025 | â0,27USD | - | 92,41 MUSD | - | 2025 Q2 |
| 2.5.2024 | â0,67USD | - | 82,25 MUSD | - | 2024 Q1 |
| 21.2.2024 | â0,64USD | - | 78,53 MUSD | - | 2023 Q4 |
| 2.8.2023 | â0,37USD | - | 108,37 MUSD | - | 2023 Q2 |
| 3.5.2023 | â0,49USD | - | 95,57 MUSD | - | 2023 Q1 |
| 22.2.2023 | â0,59USD | - | 91,64 MUSD | - | 2022 Q4 |
| 2.11.2022 | â0,43USD | - | 99,19 MUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© aktsialle Inogen
EKeskkond
20
Keskkond
SĂhiskond
20
Ăhiskond
GJuhtimus
4
Juhtimus
Eulerpool ESG Scorecard© on Eulerpool Research Systemsi rangelt autoriĂ”igustega kaitstud intellektuaalomand. Iga volitamata kasutamine, jĂ€ljendamine vĂ”i rikkumine nĂ”utakse aktiivselt ja vĂ”ib kaasa tuua mĂ€rkimisvÀÀrseid Ă”iguslikke tagajĂ€rgi. Litsentside, koostöö vĂ”i kasutamisĂ”iguste saamiseks palume vĂ”tta meiega otse ĂŒhendust meie kontaktvormi kaudu. Kontaktivorm .
Inogen aktsia aktsionÀride struktuur
| % | Nimi |
|---|---|
5,69266% | |
5,34415% | |
4,75158% | |
4,07298% | |
3,23494% | |
3,10909% |
Inogen Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
18,40% | SECÂ â | |
17,00% | SECÂ â | |
14,80% | SECÂ â | |
11,10% | SECÂ â | |
11,00% | SECÂ â | |
9,90% | SECÂ â | |
6,20% | SECÂ â | |
5,90% | SECÂ â | |
5,90% | SECÂ â | |
5,90% | SECÂ â |
Inogen Juhtkond ja nÔukogu
13 members · avg. age 59 · 38 % women
Mr. Kevin Smith (54)
President, Chief Executive Officer, Director · alates 2023
4,16 M USD
Management
Mr. Michael Bourque (62)
Chief Financial Officer, Executive Vice President, Corporate Treasurer
Mr. Kevin Smith (54)
Executive Vice President - Business Development, General Counsel, Secretary
Mr. Gregoire Ramade (55)
Executive Vice President, Chief Commercial Officer
Ms. Jennifer Boyer (51)
Chief Human Resources Officer, Executive Vice President - Enterprise Enablement
Mr. Naga Rameswamy
Chief Technology Officer
Board of Directors
Ms. Elizabeth Mora (64)
Independent Chairman of the Board
Mr. Glenn Boehnlein (63)
Independent Director
Ms. Mary Ladone (58)
Independent Director
Mr. Kevin King (68)
Independent Director
Ms. Heather Rider (65)
Independent Director
Ms. Mira Sahney (50)
Independent Director
Inogen Supply Chain
Inogen Tarneahel
Korrelatsioon: kui tihedalt liiguvad aktsiahinnad koos
| # | Nimi | Trend | |||
|---|---|---|---|---|---|
| 1 | 0,67 | 0,27 | 0,48 |
| # | Nimi | Trend | |||
|---|---|---|---|---|---|
| 1 | Apria, Inc. | â0,19 | â0,67 | â | |
| 2 | â0,43 | â0,65 | â | ||
| 3 | â0,46 | â0,40 | â0,16 | ||
| 4 | â0,07 | â0,57 | 0,04 | ||
| 5 | 0,74 | â0,02 | 0,22 |
Korduma kippuvad kĂŒsimused Inogen aktsia kohta
The business model of Inogen Inc is centered around developing and manufacturing innovative medical devices for the oxygen therapy market. Inogen primarily focuses on designing portable oxygen concentrators (POCs) that can enhance the quality of life for individuals requiring oxygen therapy. Inogen's POCs offer flexibility, mobility, and convenience, enabling patients to engage in various activities while receiving the necessary oxygen support. By providing technologically advanced and user-friendly solutions, Inogen aims to improve patient outcomes and enable individuals with respiratory conditions to lead active and independent lives. Inogen Inc is committed to meeting the evolving needs of the oxygen therapy industry by continuously developing and enhancing its product portfolio.
Inogen Inc is primarily active in the medical device industry.
The main competitors of Inogen Inc in the market are Philips Respironics and Invacare Corporation.
Inogen Inc is a renowned medical technology company specializing in the development and manufacture of portable oxygen concentrators. Founded in 2001 and based in Goleta, California, Inogen has revolutionized the industry by providing innovative and efficient oxygen therapy solutions to patients worldwide. With a strong commitment to enhancing the quality of life for those with respiratory conditions, Inogen has built a solid reputation for its cutting-edge products and exceptional customer service. The company's dedication to research, design, and manufacturing excellence has positioned it as a global leader in the oxygen therapy market, ensuring a brighter and healthier future for individuals in need of respiratory support.
Inogen Inc has achieved several significant milestones over the years. One notable achievement is the development of portable oxygen concentrators, revolutionizing the way individuals with respiratory conditions receive oxygen therapy. In 2008, the company received FDA approval for the Inogen One, its first breakthrough product. Inogen Inc has also expanded its operations globally, catering to a wider customer base across different countries. Furthermore, the company has consistently been recognized for its innovation and contributions to the medical industry. These milestones collectively highlight Inogen Inc's commitment to providing high-quality, life-enhancing solutions for individuals with respiratory needs.
Inogen Inc is primarily present in numerous countries and regions worldwide. With its focus on providing innovative and portable oxygen concentrators, Inogen has established a strong presence in various markets. The company's products and services are available across North America, including the United States and Canada, where it has a significant customer base. In addition, Inogen Inc has expanded its operations to international markets, including Europe, Australia, and Asia. Through its global distribution network and partnerships, Inogen continues to reach and serve customers in diverse geographical locations.
Inogen Inc represents values of innovation, quality, and compassion in providing portable oxygen concentrators and respiratory products. With a corporate philosophy focused on improving the quality of life for individuals with respiratory conditions, Inogen strives to enhance mobility, independence, and freedom for patients worldwide. The company's commitment to developing reliable and efficient solutions is evident through its dedication to research and development, customer service, and manufacturing excellence. Inogen Inc exemplifies its core values by providing market-leading products and exceptional support for patients to maintain an active and fulfilling lifestyle.
Analysts currently set an average price target of 13,26 USD for the Inogen stock (median: 13,26 USD), implying +130,6 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Inogen stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Inogen to generate revenue of 369,30 M USD and earnings per share of â0,77 USD.
Converted at the current exchange rate, the Inogen share trades at 4,97 EUR (5,75 USD).
The Inogen share (INGN) is listed on 4 stock exchanges, including: NASDAQ (INGN), Frankfurt (6IO.F), DĂŒsseldorf (6IO.DU), SIX (ZĂŒrich) (6IO.SW).
Inogen Inc. is a leading health company specializing in the development, manufacturing, and distribution of respiratory therapy devices. The company's main business is the production of portable oxygen concentrators which can improve the quality of life for patients with health issues. The products offered by Inogen are innovative, space-saving, and lightweight oxygen therapy devices that allow patients to maintain their breathing during daily life activities and have more freedom and independence. These devices are usually smaller and lighter than traditional oxygen systems and designed for easy transportation and operation by patients. Inogen has three main product lines: the Inogen One G5 portable oxygen concentrator, the Inogen at Home electric oxygen concentrator, and the Inogen One G4 portable oxygen concentrator. The Inogen One G5 is a portable oxygen concentrator that offers long battery life and convenient mobility. The Inogen at Home electric oxygen concentrator is a stationary system that provides continuous oxygen supply in the private home environment. The Inogen One G4 is a portable oxygen concentrator that is even smaller and lighter than the Inogen One G5. Inogen also offers accessories for the devices including additional batteries, carrying backpacks, nasal cannulas, and other replacement parts. The company sells its products in the USA and over 30 other countries worldwide. Another business segment of Inogen is the sale of devices to third-party providers including hospitals, doctors, and other healthcare professionals. Inogen provides a comprehensive range of services including service guides, installation, and customer support. Inogen has achieved success due to its technological innovation, high product quality, and customer focus. The company engages in intensive marketing to increase brand awareness and product visibility. Inogen has successful and trained team members in sales, consultation, customer care, and technical support who meet the needs of customers. Inogen follows a co-marketing model that allows them to collaborate with other healthcare partners. These partnerships help the company present its products to a wider customer segment and develop potential business opportunities. As a socially responsible company, Inogen collaborates with various non-profit organizations to achieve its goal of improving the quality of life for patients with respiratory issues. Inogen also strives to act in an environmentally conscious manner and ensures that its devices are environmentally friendly. For example, the devices' batteries are rechargeable and the materials and components are easily reusable. Overall, Inogen's business model focuses on technological innovation, customer orientation, and social responsibility. The company utilizes its core competencies and dedicated employees to create top-notch products and provide high-quality customer service. Inogen is a sound company with robust growth potential and is well-positioned to maintain its market leadership in respiratory therapy.
oodatav Inogen kÀive on 369,30 M USD. See nÀitaja pÔhineb praegusel finantsandmetel ja peegeldab ettevÔtte Àritulemuseid.
oodatav Inogen kasum on â20,84 M USD. Netokasum peegeldab ettevĂ”tte kasumlikkust pĂ€rast kĂ”igi kulude mahaarvamist.
VĂ”rdlusarvud hinna ja kasumiga (P/E) Inogen jaoks on praegu â7,50. P/E-suhtarv vĂ”rdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Inogen aktsia vÀÀrtust.
Kursuse ja mĂŒĂŒgimahu suhe (P/S) Inogen jaoks on praegu 0,42. P/S-suhtarv vĂ”rdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismÔÔdikuna Inogen aktsia jaoks.
Eulpooli kvaliteedinÀitaja Inogen jaoks on 1/10.
Inogen ISIN on US45780L1044. ISIN (rahvusvaheline vÀÀrtpaberi identifitseerimise number) on vÀÀrtpaberite globaalne unikaalne tuvastaja.
Inogen WKN on A1XB32. WKN (Wertpapierkennnummer) on kuuekohaline saksa vÀÀrtpaberi identifitseerimise number.
Inogen ticker on INGN. Ticker-sĂŒmbol kasutatakse Inogen aktsiate kauplemiseks börsil.
Inogen maksis dividende igal aastal viimase 0 aasta jooksul.
Inogen kuulub sektorisse 'Tervishoid'.
Inogen dividendid jagatakse vÀlja valuutas USD.
Inogen aktsia
Inogen konkurendid
Inogen Börsiticker
Inogen FIGI
KĂ”ik teised nĂ€itajad ja analĂŒĂŒsid Inogen kohta sĂŒgavamalt
Meie Inogen-aktsia analĂŒĂŒs sisaldab olulisi finantsnĂ€itajaid, nagu kĂ€ive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks kĂ€sitleme aspekte nagu aktsiad, turukapitalisatsioon, vĂ”lad, omakapital ja kohustused ettevĂ”ttes Inogen. Kui otsite nende teemade kohta pĂ”hjalikumat teavet, pakume teile meie alamlehtedel ĂŒksikasjalikke analĂŒĂŒse: